Lynn Seely, President and CEO of Lyell Immunopharma, Inc., filed a statement of changes in beneficial ownership on August 25, 2026, reporting an automatic sale of common stock on August 21, 2026, to cover tax obligations arising from vested restricted stock units.

Key Highlights

  • Reporting person: Lynn Seely, serving as both Director and President and CEO of Lyell Immunopharma, Inc.
  • Transaction date: August 21, 2026, with the filing submitted August 25, 2026.
  • Shares sold: 9,589 shares of common stock disposed of at $15.54 per share.
  • Purpose: According to the filing, shares were "automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."
  • Remaining ownership: Seely directly holds 63,899 shares of common stock following the transaction.
  • Issuer and trading symbol: Lyell Immunopharma, Inc., listed as NASDAQ:LYEL.

Details of Lynn Seely's Share Disposition at Lyell Immunopharma

According to the filing, Lynn Seely, who holds the roles of Director and President and CEO at Lyell Immunopharma, Inc., disposed of 9,589 shares of the company's common stock on August 21, 2026. The transaction was coded "S" and classified as a disposal. The filing states the shares were sold at a price of $15.54 each, with the transaction resulting from an automatic process tied to the settlement of vested restricted stock units.

Lyell Immunopharma, Inc. is a clinical-stage T cell reprogramming company focused on cell therapy for solid tumors, and its common stock trades on NASDAQ:LYEL. The filing notes that the sale was not a discretionary open-market transaction but rather an automatic withholding event. Following the reported disposal, Seely's direct beneficial ownership of common stock stands at 63,899 shares, as disclosed in the filing. No derivative securities transactions were reported in the filing. The form was signed by Mark Meltz as Attorney-in-Fact on August 25, 2026.

What Was Disclosed

The filing reported a single disposal of 9,589 common shares by Lyell Immunopharma's President and CEO on August 21, 2026, at $15.54 per share, executed automatically to satisfy tax withholding on settled restricted stock units, leaving the reporting person with 63,899 directly held shares.